Broadcast Date: 
  • Time: 

Gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. While the global pipeline for adeno-associated virus (AAV) gene therapy continues to expand, there are key challenges, such as characterization data to better understand AAV, that still need to be addressed. One of the fundamental characterization datasets that should be assessed, especially in a high-throughput format, is AAV capsid concentration in solution.

This webinar will highlight REGENXBIO’s experience in finding a high-throughput technology for AAV capsid concentration quantification including comparisons between Octet® AAVX Biosensors and other analytical methods. We will also present an assessment on reliability of % full capsid data generated using various methods including Octet® AAVX Biosensors, as well as case studies making use of the quantification information generated from this technology.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Sartorius logo

Comments are closed.